Table 1.
Baseline demographics and HIV-related characteristics
| Demographic characteristics | |
| Mean (SD) | |
| Age (years) | 39 (9) |
| n (%) | |
| Region of origin (n = 172) | |
| Spain | 56 (33%) |
| Europe (w/o Spain) | 29 (17%) |
| Latin America | 82 (48%) |
| Australia/Oceania | 1 (1%) |
| Asia | 1 (1%) |
| Africa | 2 (1%) |
| USA | 1 (1%) |
| Clinical characteristics | |
| Median (IQR) | |
| CD4 (cells/mm3) (n = 171) | 677 (523; 854) |
| CD8 (cells/mm3) (n = 170) | 811 (617; 1010) |
| CD4/CD8 ratio (n = 170) | 0.8 (0.6; 1.1) |
| n (%) | |
| Plasma HIV RNA-VL (copies/ml) | |
| Detectable | 24 (14%) |
| Undetectablea | 147 (86%) |
| Median (IQR) | |
| Plasma HIV RNA-VL (copies/ml) (n = 24) | 4950 (109; 88,750) |
| ART characteristics | |
| ART (n = 249)b | n (%) |
| InSTI/b or PI/b | 75 (30%) |
| InSTI | 109 (44%) |
| NNRTI | 65 (26%) |
SD standard deviation, IQR interquartile range, VL viral load, InSTI/b integrase strand transfer inhibitors boosted with cobicistat/ritonavir, PI/b protease inhibitors boosted with cobicistat/ritonavir, InSTI integrase strand transfer inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors.
aUndetectable VL: < 50 copies/ml
b249 treatment regimens (in 172 patients), 1 year before and 1 year after the baseline visit